Status:
COMPLETED
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physici...
Detailed Description
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physici...
Eligibility Criteria
Inclusion
- Known diagnosis of NET, suspected SSTR positive tumors or suspected NET recurrence.
- At least 18 years of age.
- Patient or patient's legally acceptable representative cognitively provides written informed consent.
- Able to provide informed consent.
- Females of childbearing potential must have a negative pregnancy test at screening/baseline.
Exclusion
- Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.
- Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result.
- Inability to lie still for the entire imaging time.
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Recognized concurrent active infection.
- Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
Key Trial Info
Start Date :
August 26 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01873248
Start Date
August 26 2013
End Date
June 16 2017
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology
Los Angeles, California, United States, 90095